MedTrace Logo

Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

NCT01009970 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-10-13

No results posted yet for this study

Summary

This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to study the feasibility of R-COMP in this cohort of patients.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Rituximab

375 mg/m2 day 1

DRUG

Cyclophosphamide

750 mg/m2 day 2

DRUG

Vincristine

1,4 mg/m2 (max 2 mg) day 2

DRUG

Prednisone

40 mg/m2 day 2-6

DRUG

Doxorubicin

50 mg/m2 day 2

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Michele Spina, MD · Centro di riferimento Oncologico di Aviano

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-05-31
Completion
2012-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01009970 on ClinicalTrials.gov